In patients meeting the eligibility requirements for the DAPA-CKD trial, dapagliflozin is likely to be a cost effective treatment within the UK, German, and Spanish health care systems, as per new research.
Chronic Kidney Disease (CKD) imposes a significant burden on patients and health care providers, particularly upon reaching kidney failure when patients may require kidney replacement therapy (KRT). The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial demonstrated that dapagliflozin, with standard therapy, reduced CKD progression and KRT requirement.
DAPA-CKD was a randomized, double-blind, placebo-controlled, event-driven trial in patients with eGFR 25 to 75 ml/min per 1.73 m2 and albuminuria. The trial evaluated the efficacy and safety of dapagliflozin 10 mg once daily versus placebo in addition to current standard therapy.
Results were consistent across UK, German, and Spanish health care settings and important patient subgroups, and they were primarily driven by attenuating disease progression, thereby delaying initiation of dialysis and kidney transplantation and reducing rates of hospitalization for heart failure and death.
